A 2025 systematic review by Vasireddi and colleagues in HSS Journal screened 544 published papers and identified 36 meeting inclusion criteria 35 preclinical studies and only one human study: an uncontrolled, unblinded, retrospective case series of 12 patients receiving intra-articular BPC-157 for chronic knee pain, in which 7 of 12 (58%) reported self-described relief lasting more than 6 months, with no dose, effect size, or systematically collected adverse events published
BPC157 promotes tissue repair by enhancing blood flow and cellular regeneration, while TB500 helps reduce inflammation and improves flexibility by supporting cell movement and new blood vessel growth
Therefore, GABAergic/glutamatergic transmission, which involves inhibitory and excitatory neurotransmitters in the brain, can be targeted for MS treatment [15]
If nothing shifts within 23 weeks, its time to revisit dose, delivery method, or stacking options with your provider